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Abstract
This systematic review aims to assess the efficacy of aromatase inhibitors (AIs) in treating pain symptoms caused
by endometriosis. A comprehensive literature search was conducted to identify all the published studies evaluating
the efficacy of type II nonsteroidal aromatase inhibitors (anastrozole and letrozole) in treating endometriosis-related
pain symptoms. The MEDLINE, EMBASE, PubMed, and SCOPUS databases and the Cochrane System Reviews were
searched up to October 2010. This review comprises of the results of 10 publications fitting the inclusion criteria;
these studies included a total of 251 women. Five studies were prospective non-comparative, four were
randomized controlled trials (RCTs) and one was a prospective patient preference trial. Seven studies examined the
efficacy of AIs in improving endometriosis-related pain symptoms, whilst three RCTs investigated the use of AIs as
post-operative therapy in preventing the recurrence of pain symptoms after surgery for endometriosis. All the
observational studies demonstrated that AIs combined with either progestogens or oral contraceptive pill reduce
the severity of pain symptoms and improve quality of life. One patient preference study demonstrated that
letrozole combined with norethisterone acetate is more effective in reducing pain and deep dyspareunia than
norethisterone acetate alone. However, letrozole causes a higher incidence of adverse effects and does not
improve patients’ satisfaction or influence recurrence of symptoms after discontinuation of treatment. A RCT
showed that combining letrozole with norethisterone acetate causes a lower incidence of adverse effects and
lower discontinuation rate than combining letrozole with triptorelin. Two RCTs demonstrated that, after surgical
treatment of endometriosis, the administration of AIs combined with gonadotropin releasing hormone analogue
for 6 months reduces the risk of endometriosis recurrence when compared with gonadotropin releasing hormone
analogue alone. In conclusion, AIs effectively reduce the severity of endometriosis-related pain symptoms. Since
endometriosis is a chronic disease, future investigations should clarify whether the long-term administration of AIs
is superior to currently available endocrine therapies in terms of improvement of pain, adverse effects and patient
satisfaction.
Background
Endometriosis is a chronic estrogen dependent gynaeco-
logical condition characterized by the presence of ecto-
pic glands and stroma outside the uterine cavity. It
affects at least 3.6% of women [1] and it often causes
infertility and/or pain symptoms (dysmenorrhea, deep
dyspareunia, chronic pelvic pain and dyschezia). In
some patients, pain symptoms are extremely severe and
negatively affect quality of life, work efficiency and
sexual life [2-4]. Several hormonal therapies have been
proposed for the treatment of endometriosis related
pain, including oral contraceptive pill and other estro-
progestin formulations (such as the vaginal ring and the
transdermal patch), progestins (such as medroxyproges-
terone acetate, norethisterone acetate and the levonor-
gestrel-releasing intrauterine device), gonadotrophin
releasing hormone analogues and danazol [5]. These tra-
ditional endocrine therapies for endometriosis inhibit
estrogens production in the ovary. However, in some
patients, pain symptoms may persist despite the use of
endocrine therapies.
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either on polymerase chain reaction or immunohisto-
chemistry have demonstrated that aromatase P450 is
over-expressed in both eutopic and ectopic endome-
trium of patients with endometriosis, while this enzyme
is not detectable in eutopic endometrium obtained from
healthy women and in endometriosis free peritoneal tis-
sue [6-13]. Although the aromatase P450 can been
detected in both epithelial and stromal cells obtained
from ectopic and eutopic endometrium of women with
endometriosis, its expression is higher in epithelial than
in stromal cells. In contrast with majority of the litera-
ture, some recent studies questioned the aberrant
expression of the aromatase P450 in endometriosis
[14-16]. Delvoux et al. reported the absence of aroma-
tase P450 in eutopic and ectopic tissue obtained from
women with endometriosis [14]. In addition, it was
demonstrated that endometriotic lesions could create a
hyperestrogenic environment increasing the reduction of
estrone into 17-b estradiol and decreasing the oxidation
of 17-b estradiol into estrone [14]. In agreement with
these observations, Colette et al. found that aromatase
P450 is undetectable by immunohistochemistry in the
glandular and stromal compartments of ectopic endo-
metrial tissue [16]. Furthermore, the authors showed
that the expression of the aromatase gene, measured by
quantitative polymerase chain reaction using three dif-
ferent protocols, is low in endometriomas and barely
detectable in only a small percentage of eutopic endo-
metrial samples, peritoneal lesions and rectovaginal
nodules [16]. The authors suggested that what was
believed to be aromatase protein was mainly endogen-
ous biotic labeling or iron deposits [15].
Based on the molecular observations of increased
expression of aromatase P450 in endometriotic tissue
published over the last ten years, some authors used
aromatase inhibitors (AIs) to treat pain symptoms in
premenopausal women with endometriosis [17,18]. This
systematic review was performed to assess the efficacy
of AIs in treating pain symptoms caused by
endometriosis.
Methods
This systematic review was carried out according to the
MOOSE guidelines [19]. No institutional review board
approval was required because only published, de-identi-
fied data were analysed.
Identification of the literature
A systematic literature search was performed to identify
all the published studies evaluating the efficacy of AIs in
treating pain symptoms associated with endometriosis.
The search included the combination of the following
medical subjects heading terms: “endometriosis”, “deep
endometriosis”, “deeply infiltrating endometriosis”, “rec-
tovaginal endometriosis”, “ovarian endometriosis”,
“endometriomas”, “bowel endometriosis”, “bladder endo-
metriosis”, “dysmenorrhea”, “pelvic pain”, “deep dyspar-
eunia”, “medical therapy/treatment”, “aromatase
inhibitors”, “letrozole” and “anastrozole”.
The following electronic databases were searched
MEDLINE, EMBASE, PubMed, SCOPUS and the
Cochrane System Reviews from inception until October
2010.
All pertinent articles were examined and their refer-
ence lists were systematically reviewed in order to iden-
tify other studies for potential inclusion in this
systematic review. Review articles, books and mono-
graphs published on endometriosis were consulted and
their reference lists were systematically searched to
identify further studies that could be reviewed.
No language restriction was applied. The search was
run every month between January 2009 and October
2010 to identify new articles.
Study selection
Randomised controlled trials (RCTs), patient preference
trials and observational studies were included in this
review, whereas case reports, abstracts and proceedings
of scientific meetings were excluded.
The studies included in the current review were
selected accordingly to the following criteria:
- Population. Premenopausal women with diagnosis of
endometriosis (either as a primary or recurrent disease)
based at least on vaginal and/or rectal examination; ide-
ally on previous surgery and histological examination of
the lesions. Patients complaining of pain symptoms such
as dysmenorrhea, deep dyspareunia, chronic pelvic pain
and dyschezia.
- Interventions. Treatment of pain symptoms with
third generation nonsteroidal (type II) AIs either alone
or in combination with other hormonal therapies.
- Design. The minimum number of individuals in each
trial was 10. The minimum size of follow-up was 80% or
more, though there was no minimum length of follow-
up. Assessment of the intensity of pain symptoms by
using standardised scales such as the visual analogue
scale (VAS).
- Outcome. Changes in the intensity of endometriosis-
related pain symptoms during treatment with AIs either
alone or combined with other hormonal therapies but
not combined with surgery (primary outcome). Efficacy
of AIs either alone or combined with other hormonal
therapies in preventing the recurrence of pain after sur-
gical treatment of endometriosis (secondary outcome).
The abstract of studies retrieved in the search were
reviewed by two authors (S.F. and D.J.G.) to exclude
citations deemed irrelevant. The reviewers worked
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between the two reviewers was resolved by consensus or
arbitration by a third reviewer (V.R.). The reviewers
were not blinded to the names of investigators or
sources of publication.
Data extraction
Data were extracted from each article and collected in
standardised forms in duplicate by two reviewers (S.F.
and D.J.G.). A final abstraction form was compiled from
the two evaluation forms, with correction and resolution
of any discrepancy between reviewers by consensus
reached after discussion or arbitration by a fourth
reviewer (P.L.V.).
Results
Study identification
Figure 1 shows the flow diagram of the literature search
results. The search identified 231 articles of which 28
abstracts reported findings on the treatment of endome-
triosis with aromatase inhibitors. These articles were
retrieved for detailed assessment. Of the 28 studies
found, 4 were excluded because they were only pub-
lished in the abstracts or proceedings of scientific meet-
ings [20-23], 12 were excluded because they were case
r e p o r t so ri n c l u d e dl e s st h a n1 0p a t i e n t s[ 2 4 - 3 5 ] ,1
study was excluded because of duplicate publication [36]
and 1 study was excluded because the instruments used
to describe the changes in pain symptoms during treat-
ment were not clearly defined [37].
Characteristics of the included studies
Data on the efficacy of AIs in treating endometriosis-
related pain symptoms were extracted from the remain-
ing 10 articles, all of which were published in full in
peer-reviewed journals between 2004 and October 2010
[38-47]. Of the ten included studies, five were prospec-
tive non-comparative [38,39,41-43], four were RCTs
Figure 1 Study selection flow chart.
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trial [44]. Four studies were performed in Italy
[42-44,47] two in USA [38,40], two in Iran [45,46], one
in Turkey [39] and one in Austria [41]. A total of 251
women with endometriosis treated with aromatase inhi-
bitors were found, of which 62 were in prospective non-
comparative studies, 148 were in RCTs and 41 in the
patient-preference trial. A total of 183 patients were
treated with letrozole and 68 patients were treated with
anastrozole. The AI was administered vaginally in one
study [41], in all the other studies it was administered
orally. Three studies investigated the use of AIs as post-
operative therapy in preventing the recurrence of pain
after surgical treatment of endometriosis [39,45,46];
seven studies examined the effect of AIs in improving
endometriosis-related pain symptoms. The characteris-
tics of the studies included in the review are described
in Table 1.
Changes in the intensity of endometriosis-related pain
symptoms during treatment with AIs (primary outcome)
Seven studies included in this review investigated the
efficacy of AIs in treating endometriosis-related pain
symptoms (Table 2).
Prospective non-comparative studies
In an open-label, phase 2, nonrandomised prospective
study, Ailawadi et al. examined the efficacy of letrozole
in treating reproductive age women with endometriosis
and chronic pelvic pain [38]. The study included ten
women with endometriosis-related pain symptoms that
persisted after previous surgical and medical treatment.
In particular, each patient had at least one course of
treatment with leuprolide acetate for 3-6 months before
enrolment in the study. Each patient underwent a diag-
nostic laparoscopy to histologically confirm the diagno-
sis of endometriosis and establish the ASRM stage of
the disease. No ablation of endometriotic lesions was
performed. Letrozole (2.5 mg/day) and norethisterone
acetate were administered within 1 month from laparo-
scopy and continued for 6 months. During the first
month of treatment, pain score improved in 9 patients
(90.0%). At the completion of the 6-month treatment,
there was a significant decrease in the intensity of pain
symptoms. Only one patient (10.0%) had persistent pain
during treatment. In addition, a second laparoscopy per-
formed within 2 months of the completion of therapy
demonstrated that the treatment improved the ASRM
stage of endometriosis.
In another open-label, phase 2, non-randomised pro-
spective study, Amsterdam et al. treated with anastra-
zole (1 mg/day) and oral contraceptive pill 18 women
with endometriosis and chronic pelvic pain refractory to
multiple medical and surgical treatments [40]. 15
women (83.3%) completed the 6-month treatment.
Three patients interrupted the therapy because of persis-
tence of pain in one case, anxiety in another case and
loss to follow-up in another case. Improvements in pain
symptoms were observed at 1 month after commencing
the treatment. At the completion of the study, a signifi-
c a n tr e d u c t i o ni nt h ei n t e n s i t yo fp e l v i cp a i nw a s
reported in 14 of 15 patients (93.3%).
Hefler et al. administered anastrozole (0.25 mg/day) in
a vaginal suppository to 10 women with histologically
confirmed rectovaginal endometriosis [41]. After 6
months of treatment, an improvement in dysmenorrhea
was observed in all but one patient; however, the base-
line intensity of dysmenorrhea in the study population
was unusually low (3.6 cm on the VAS scale) for a
population of patients with rectovaginal endometriosis.
The intensity of chronic pelvic pain and dyspareunia
was unchanged by treatment, as was the number of days
with the use of analgesic. The therapy resulted in a sig-
nificant improvement in quality of life (measured by the
Short Form-36). Data on the changes in the volume of
the rectovaginal endometriotic nodules during the six-
month treatment were reported in 9 women; the volume
decreased in three patients, remained stable in three and
increased in three. Three patients (30%) underwent sur-
gery after the completion of treatment.
More recently, in an open-label prospective study,
Remorgida et al. administered letrozole (2.5 mg/day)
and desogestrel to 12 women with endometriosis-related
pain symptoms that were refractory to previous medical
and surgical treatments [42]. All the patients interrupted
the treatment after a median time of 84 days (range, 56-
112 days) because of the development of functional
ovarian cysts and 8 women (66.7%) developed more
than one ovarian cyst. At the interruption of treatment,
the intensity of dyspareunia was significantly decreased
when compared with baseline values. In contrast, no sta-
tistically significant change was observed in the reported
intensity of chronic pelvic pain. Pain symptoms recurred
after the discontinuation of treatment and at 6-month
follow-up their intensity was similar to baseline values.
In a further open-label prospective study, Remorgida
et al. administered letrozole (2.5 mg/day) and norethis-
terone acetate to 12 women with histologically con-
firmed rectovaginal endometriosis [43]. The intensity of
deep dyspareunia and chronic pelvic pain dropped sig-
nificantly after only 1 month of treatment and contin-
ued to decrease during therapy. After 6-month
treatment, the intensity of chronic pelvic pain and deep
dyspareunia were significantly lower than at baseline; in
addition, there was a significant improvement in quality
of life (measured by the Short Form-36). Pain symptoms
recurred after discontinuation of treatment and, after 6
months from the completion of treatment there was no
significant difference in the intensity of pain symptoms
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Authors Year Study
design
Number
of
subjects
Age of the
patients
(years)
Diagnostic
modality
Characteristics
of
endometriosis
Intervention:
aromatase
inhibitor
Intervention: other
hormonal therapies
Intervention: non-
hormonal therapies
Post-
operative
treatment
Length of
treatment
Criteria
for pain
evaluation
Ailawadi et
al. [38]
2004 Prospective
non-
comparative
trial
10 29.9 (22-45)
a histology ASRM stage
b:
stage 1, n = 1
stage 2, n = 1
stage 3, n = 3
stage 4, n = 6
oral: letrozole
2.5 mg/day
oral: norethisterone
acetate 2.5 mg/day
oral: elemental calcium
1250 mg/day, vitamin
D 800 I.U./day
no 6 months VAS
Soysal et al.
[39]
2004 Randomised
controlled
trial
40 31.3 ± 5.7
b surgery ASRM stage
b:
stage 4, n = 40
oral:
anastrozole 1
mg/day
subcutaneous:
goserelin 3.6 mg/4
weeks
oral: elemental calcium
1200 mg/day, vitamin
D 800 I.U./day
yes 6 months TPSS
Amsterdam
et al. [40]
2005 Prospective
non-
comparative
trial
18 23-46
c surgery NA oral:
anastrozole 1
mg/day
oral: ethinyl estradiol
20 μg/day,
levonorgestrel 0.1 mg/
day
none no 6 months VAS
Hefler et al.
[41]
2005 Prospective
non-
comparative
trial
10 31.2 ± 4.3
b histology rectovaginal
endometriosis
vaginal:
anastrozole
0.25 mg/day
none oral: elemental calcium
1200 mg/day, vitamin
D 800 I.U./day
no 6 months VAS
Remorgida
et al. [42]
2007 Prospective
non-
comparative
trial
12 32.8 ± 3.2
b surgery, US,
MRI
ASRM stage
b:
stage 4, n = 12
oral: letrozole
2.5 mg/day
oral: desogestrel 75
μg/day
oral: elemental calcium
1000 mg/day, vitamin
D 880 I.U./day
no 6 months VAS
Remorgida
et al. [43]
2007 Prospective
non-
comparative
trial
12 32.3 ± 3.8
b histology,
US, MRI
rectovaginal
endometriosis
oral: letrozole
2.5 mg/day
oral: norethisterone
acetate 2.5 mg/day
oral: elemental calcium
1000 mg/day, vitamin
D 880 I.U./day
no 6 months VAS
Ferrero et
al. [44]
2009 Prospective
patient
preference
trial
41 31.2 ± 4.6
b histology,
US
rectovaginal
endometriosis
oral: letrozole
2.5 mg/day
oral: norethisterone
acetate 2.5 mg/day
oral: elemental calcium
1000 mg/day, vitamin
D 880 I.U./day
no 6 months VAS
Roghaei et
al. [45]
2010 Randomised
controlled
trial
38 32.3 ± 6.0
b surgery NA oral: letrozole
2.5 mg/day
none oral: elemental calcium
1000 mg/day, vitamin
D 880 I.U./day
yes 6 months 11-item
scale
Alborzi et
al. [46]
in
press
Randomised
controlled
trial
47 29.2 ± 5.3
b histology ASRM stage
b:
stage 1-2, n =
24
stage 3-4, n =
23
oral: letrozole
2.5 mg/day
none none yes 2 months VAS
Ferrero et
al. [47]
in
press
Randomised
controlled
trial
35 35.1 ± 3.8
b surgery, US rectovaginal
endometriosis
oral: letrozole
2.5 mg/day
oral
norethisterone acetate
2.5 mg/day (n = 17)
or
intramuscular
triptorelin 11.25 mg/3
months (n = 18)
oral: elemental calcium
1000 mg/day, vitamin
D 880 I.U./day
no 6 months VAS and
VRS
a mean, range;
b mean ± SD;
c range
US = ultrasonography; MRI = magnetic resonance imaging; ASRM = American Society for Reproductive Medicine stage of endometriosis [51]; VAS = visual analogue scale; TPSS = total pelvic symptom score; VRS =
verbal rating scale; NA = not available
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0when compared with pre-treatment values. Five patients
(41.7%) underwent surgery at 7.0 (± 2.5) months after
the completion of therapy.
Prospective patient-preference study
In a prospective, open-label, patient preference study
including 82 women with rectovaginal endometriosis,
Ferrero et al. compared the efficacy and tolerability of
letrozole (2.5 mg/day) combined with norethisterone
acetate with norethisterone acetate alone [44]. At the
completion of treatment, no significant difference was
observed in patient satisfaction between the two study
groups; 63.4% of the patients receiving norethisterone
acetate alone and 56.1% of those receiving the double-
drug regimen were either satisfied or very satisfied with
the treatment. At both 3 and 6 months of treatment,
the intensity of chronic pelvic pain and deep dyspareu-
nia were significantly decreased when compared with
baseline values in the two study groups. In line with this
observation, the use of analgesic medications signifi-
cantly decreased during the treatment in both study
groups. However, at both 3-and 6-month assessment,
the intensity of chronic pelvic pain and deep dyspareu-
nia were significantly lower in women receiving the dou-
ble-drug regimen than in those receiving norethisterone
acetate alone. Pain symptoms quickly recurred after the
discontinuation of treatment without significant differ-
ences between the two study groups. Adverse effects of
treatment were significantly more frequent in patients
treated with the double drug-regimen (43.2%) than in
those receiving norethisterone acetate alone (18.4%; p =
0.020). The authors concluded that the combination
drug regimen was more effective in reducing pain and
deep dyspareunia than norethisterone acetate alone.
However, letrozole caused a higher incidence of adverse
effects and did not improve patient satisfaction or delay
recurrence of symptoms after discontinuation of
treatment.
Randomised controlled study
In a RCT, Ferrero et al. assigned symptomatic women
with rectovaginal endometriosis treated with letrozole
Table 2 Main results of the studies investigating the efficacy of AIs in improving endometriosis-related pain
symptoms
Authors Year Pain at
baseline
(mean ± SD)
Pain et the
end of
treatment
(mean ± SD)
Completion
of
treatment
(%, n)
Quality of life
during
treatment
(instrument)
Satisfaction
with
treatment
(%,n)
Lesion size
at baseline
(cm
3)
Lesion size at
the end of
treatment (cm
3)
Ailawadi et
al. [38]
2004 pain score 6.22 ± 2.07 2.52 ± 2.09 100% (10/10) N.A. N.A. N.A. N.A.
Amsterdam
et al. [40]
2005 pain score 8.70 ± 1.76 3.20 ± 2.70 83.3% (15/
18)
N.A. N.A. N.A. N.A.
Hefler et al.
[41]
2005 dysmenorrhea
chronic pelvic
pain
3.6 ± 1.9
1.9 ± 1.4
3.1 (1.6)
1.9 (1.3)
100% (10/10) Improved (SF-36) N.A. 4.2
(median)
4.2 (median)
Remorgida
et al. [42]
2007 dysmenorrhea
deep
dyspareunia
chronic pelvic
pain
8.7 ± 1.9
6.5 ± 2.7
6.0 ± 1.9
0.8 ± 0.7
0.6 ± 0.5
3.2 ± 2.6
0% (0/12) N.A. N.A. N.A. N.A.
Remorgida
et al. [43]
2007 dysmenorrhea
deep
dyspareunia
chronic pelvic
pain
8.8 ± 1.0
7.6 ± 1.5
5.6 ± 0.9
3.7 ± 2.2
2.2 ± 2.0
2.4 ± 1.6
100% (10/10) Improved (SF-36) N.A. N.A. N.A.
Ferrero et
al. [44]
2009 deep
dyspareunia
chronic pelvic
pain
6.6 ± 2.1
5.9 ± 1.6
1.7 ± 1.1
1.5 ± 1.4
90.2% (37/
41)
N.A. 56.1% (23/41) N.A. N.A.
Ferrero et
al. [47]
in
press
Triptorelin
group
deep
dyspareunia
chronic pelvic
pain
Norethisterone
acetate group
deep
dyspareunia
chronic pelvic
pain
6.4 ± 1.9
6.1 ± 1.4
6.6 ± 2.1
6.0 ± 1.4
2.0 ± 0.9
1.2 ± 1.3
2.2 ± 1.4
2.0 ± 1.8
55.6% (10/
18)
94.1% (16/
17)
N.A.
N.A.
22.2% (4/18)
64.7% (11/17)
3.2 (mean)
3.4 (mean)
2.8 (mean)
3.0 (mean)
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triptorelin for 6 months [47]. The study was ended pre-
term based on the results of an interim analysis, which
was performed when 35 women had been recruited.
The interim analysis showed that a significantly higher
number of patients interrupted the treatment because of
adverse effects when letrozole was combined with trip-
torelin (44.4%; 8/18) than when it was combined with
norethisterone acetate (5.9%, 1/17; p = 0.018). In line
with this finding, the percentage of women satisfied
with treatment was significantly higher in those treated
with norethisterone acetate (64.7%) than in those treated
with triptorelin (22.2%; p = 0.028). The intensity of both
chronic pelvic pain and deep dyspareunia significantly
decreased during treatment in both study groups,
though no meaningful difference between the two
groups was apparent. After 6 months of treatment, there
was a significant reduction in the volume of the rectova-
ginal nodules in both study groups; however, the reduc-
tion in the volume of endometriotic nodules was
significantly greater in patients receiving triptorelin
(16.1%) than in those receiving norethisterone acetate
(10.2%).
Prevention of symptom recurrence after surgery for
endometriosis (secondary outcome)
Three RCTs examined whether the postoperative
administration of AIs reduces the risk of endometriosis
recurrence after surgery for endometriosis [39,45,46]
(Table 3). Soysal et al. randomised 80 women who
underwent radical surgical treatment of severe endome-
triosis to receive either goserelin and anastrozole or
goserelin alone for 6 months [39]. All the patients
included in the RCT received elemental calcium and
vitamin D. The RCT found that the double-drug
regimen reduced the proportion of women experiencing
recurrence of pain at 24 months’ follow-up compared
with goserelin alone (8% with combination treatment
versus 35% with goserelin alone). Furthermore, combi-
nation treatment significantly increased the median time
to symptom recurrence compared with goserelin alone
(greater than 2.4 months with combination treatment
versus 1.7 months with goserelin alone; RR 4.3, 95% CI
1.3 to 9.8; p = 0.0089). At the completion of treatment
the menopausal quality of life (measured by the modi-
fied Greene scale and the Blatt-Kupperman Index) was
not statistically significant different between the two
study groups.
In another RCT, Roghaei et al. randomised 106
women with endometriosis who underwent cauterization
of the lesions to receive one of the following treatments:
letrozole (2.5 mg/day; n = 38), danazol (600 mg/day; n =
37) or placebo (n = 31) for 6 months [45]. All the
patients included in the RCT also received elemental
calcium and vitamin D. The study showed that, during
the treatment, the intensity of dyspareunia, dysmenor-
rhea and chronic pelvic pain decreased in each study
group. However, at the end of the treatment, the inten-
sity of pain symptoms was significantly lower in patients
treated with letrozole or danazol than in those treated
with placebo. Unfortunately, no follow-up was reported
after the discontinuation of the hormonal therapy.
Alborzi et al. randomised 144 infertile women who
underwent laparoscopic excision of endometriotic
lesions to be treated with letrozole (2.5 mg/day), triptor-
elin (3.75 mg/every 4 weeks) or placebo for 2 months
[46]. The rate of recurrence of endometriosis was simi-
lar in the three groups. At one year after the restoration
of the menstrual cycle, recurrence of endometriosis was
observed in 6.4% of the patients treated with letrozole,
Table 3 Main results of the three RCT investigating the efficacy of AIs in preventing symptoms recurrence after
surgery for endometriosis (secondary outcome)
Authors Treatment Length of
treatment
Length of follow-up after
discontinuation of
hormonal therapy
Results
Soysal et
al. [39]
- anastrozole (1 mg/day) or
placebo
- goserelin 3.6 mg/4 weeks
- elemental calcium (1200
mg/day), vitamin D (800 I.U./
day)
6 months 24 months The recurrence rate was 7.5% (3/40) in patients receiving
anastrozole and goserelin and 35.0% (14/40) in patients
receiving goserelin alone.
The median time to detect symptom recurrence was > 24
months in patients receiving anastrozole and goserelin and 17
months in patients receiving goserelin alone.
Roghaei
et al.
[45]
- letrozole 2.5 mg/day or
danazol (600 mg/day) or
placebo
- elemental calcium (1000
mg/day), vitamin D (880 I.U./
day)
6 months 0 months At the end of the treatment, the intensity of pain symptoms
was significantly lower in patients treated with letrozole or
danazol than in those treated with placebo.
Alborzi
et al.
[46]
letrozole (2.5 mg/day) or
triptorelin (3.75 mg/4 weeks)
or no treatment
2 months 12 months The rate or recurrence was 6.4% (3/47) in patients treated with
letrozole, 5.0% (2/40) in patients treated with triptorelin and
5.3% (3/57) in patients receiving no treatment (not significant).
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receiving placebo (not significant). In addition, no signif-
icant difference was observed in the pregnancy rates of
women included in the three study groups (23.4% in
patients treated with letrozole, 27.5% in those treated
with triptorelin and 28.1% in those receiving placebo).
Discussion
All the observational studies included in this review
[38,40-43], one patient-preference trial [44] and one
RCT [47] demonstrated that AIs combined with either
progestogens, oral contraceptive pill or gonadotropin
releasing hormone analogue reduce the intensity of pain
symptoms caused by endometriosis (Table 2). In addi-
tion, two observational studies showed that the adminis-
tration of AIs improves quality of life [41,43]. The effect
of AIs on the volume of rectovaginal endometriotic
nodules remains unclear. In one observational non-com-
parative study [41], the administration of vaginal ana-
strozole (0.25 mg/day) for 6 months did not cause a
decrease in the volume of rectovaginal endometriotic
nodules. In contrast, a RCT [47] showed that the oral
administration of letrozole (2.5 mg/day) combined with
either gonadotropin releasing hormone analogue or pro-
gestogen significantly reduces the size of rectovaginal
endometriotic nodules.
Endometriosis is a chronic disease [48] and pain typi-
cally recurs to a degree similar to that at baseline after
discontinuation of endocrine therapies [49,50]. Most of
the published observational non-comparative studies did
not report a follow-up after discontinuation of treatment
with AIs [38,40,41,47]. Two observational non-compara-
tive studies [42,43] and one patients-preference trial [44]
observed a quick recurrence of pain symptoms after dis-
continuation of therapy with AIs. In particular, after 6
months from the completion of the treatment, the
intensity of pain symptoms was similar to pre-treatment
values [42-44]. Furthermore, patients with persistent
pain symptoms during the administration of AIs have
been found to have rectovaginal nodules with preserved
glandular epithelium and abundant stromal cells having
proliferative activity [43].
The adverse effects caused by AIs in premenopausal
women (such as arthralgia and myalgia) may be more
severe than those caused by progestogens and oral con-
traceptive pill thus reducing the compliance of the
patients in the long-term treatment. Recently, a patient
preference study demonstrated that letrozole and nor-
ethisterone acetate are more effective in reducing pain
and deep dyspareunia than norethisterone acetate;
although the AI resulted in a higher incidence of
adverse effects [44]. As a consequence patients’ satisfac-
tion was not improved by the administration of letrozole
combined with norethisterone acetate when compared
with norethisterone acetate alone [44]. In this perspec-
tive, it is preferable to combine AIs with progestogens
rather than with gonadotropin releasing hormone analo-
gues. In fact a RCT showed that combining the AI with
norethisterone acetate causes a lower incidence of
adverse effects and lower discontinuation rate than com-
bining letrozole with triptorelin [47].
AIs may have a role in the prevention of recurrence
after surgical treatment of endometriosis. Two RCTs
[ 3 9 , 4 5 ]d e m o n s t r a t e dt h a tt h ea d m i n i s t r a t i o no fA I s
(alone or combined with gonadotropin releasing hor-
mone analogue) for 6 months reduces the risk of endo-
metriosis recurrence when compared with postoperative
treatment with gonadotropin releasing hormone analo-
gue or danazol. In contrast, one RCT demonstrated that
the postoperative administration of AIs for only 2
months does not decrease the risk of endometriosis
recurrence when compared with gonadotropin releasing
hormone analogue or placebo [46].
The heterogeneity of the analyzed studies is an impor-
tant limitation of the current systematic review. In fact,
AIs were administered either alone or in combination
with various hormonal therapies (progestin, oral contra-
ceptive pill or gonadotropin releasing hormone analo-
gues). In addition, the severity of endometriosis was
established accordingly to the classification of the Amer-
ican Society for Reproductive Medicine (ASRM) only in
four studies [51]; furthermore, two of these studies
included women with various stage of disease. Four stu-
dies included patients with rectovaginal endometriosis,
but the severity of the disease was not established
accordingly to the ASRM classification. A further limita-
tion of this review consists in the fact that AIs were
administered only for a relatively short period of time
(from two to six months). Despite these important lim-
itations, the findings of the analysed studies suggest the
efficacy of AIs in the short-term treatment of endome-
triosis-related pain symptoms. However, women with
endometriosis should receive a chronic treatment [5,48]
and the optimal therapy should balance potential bene-
fits and side affects. In this perspective, the role of AIs
in the long-term treatment of pain symptoms caused by
endometriosis remains uncertain because of the persis-
tence of endometriotic lesions during treatment [43]
and of the high incidence of the side effects observed
not only in women with endometriosis [44,47] but also
in premenopausal breast cancer patients [52]. In addi-
tion, there are several concerns on the safety of a long-
term administration of AIs to premenopausal women.
Third-generation AIs negatively affect bone health
[53,54]. They suppress aromatase activity within the
osteoblasts presumably favouring increased osteoclastic
activity and net loss of bone mineral density [53]. One
RCT included in this review [47] and studies performed
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that a 6 month treatment with AIs and gonadotropin
releasing hormone analogue significantly decrease bone
mineral density. The hypoestrogenism caused by AIs
may be associated with other adverse effects. Studies
performed in breast cancer patients showed that AIs
may lack the lipid lowering and cardioprotective effect
of tamoxifen, but they do not seem to increase the risk
of cardiovascular events [56]. However, data on the
effects of AIs on cardiovascular disease is limited, parti-
cularly in premenopausal women.
Given this background, it seems unlikely that AIs, parti-
cularly combined with gonadotropin releasing hormone
analogues, may be used as a standard long-term treatment
of premenopausal endometriosis. Combining AIs with
other hormonal therapies (such as norethisterone acetate)
may decrease the incidence of adverse affects and reduce
the loss of bone mineral density. However, only women
failing to improve after the administration of standard
endocrine therapies and surgical excision of endometriosis
may be candidate to receive AIs. These agents should be
prescribed only to women with histologically proven endo-
metriosis and normal mineral bone density. In addition,
before starting the treatment, patients should be informed
in details of the potential adverse effects caused by AIs,
particularly musculoskeletal symptoms.
Conclusions
In conclusion, this systematic review suggests that AIs
effectively reduce the severity of endometriosis-related
pain symptoms. Since endometriosis is a chronic disease,
future investigations should clarify whether the long-
term administration of AIs is superior to currently avail-
able endocrine therapies in terms of improvement of
pain, adverse effects and patient satisfaction. The poten-
tial risks caused by the hypoestrogenism associated with
the administration of AIs (particularly on bone mineral
density) should always be considered before prescribing
these agents to premenopausal women. On the basis of
the available data, aromatase inhibitors should now be
offered only to women who have severe pain despite pre-
vious surgical and hormonal therapies [18].
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